Skip to content

Study · Non-randomized trial · 2018

1 result

Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.

Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J

Diabetes, obesity & metabolism21 Aug 2018Cited by 15 (Europe PMC)

PMID29923298 (opens in a new tab)PMCIDPMC6221077 (opens in a new tab)DOI10.1111/dom.13444 (opens in a new tab)PepBankPUB-29923298
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialSafety outcome

    In LixiLan-O patients with type 2 diabetes, 27.5% of lixisenatide-alone recipients experienced gastrointestinal adverse events during the initial treatment weeks.

    In plain wordsDuring the initial treatment weeks, 27.5% of patients receiving lixisenatide alone reported stomach or bowel side effects.

    Peptide
    Lixisenatide
    Outcome
    Not applicableInitial gastrointestinal adverse-event incidence
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    GI adverse-event incidence
    27.5%
    lixisenatide alone, LixiLan-O

    Source sentences

    Summary
    In iGlarLixi-treated patients, the rate of GI AEs during the initial weeks of treatment was lower versus patients treated with lixisenatide alone (9.6% and 11.7% of iGlarLixi-treated patients in LixiLan-L and LixiLan-O, respectively, vs. 27.5% of lixisenatide-treated patients in LixiLan-O).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02058147

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Sanofin = 1,170Feb 2014 to Jun 2015

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 May 2017
CompletedPhase 3Results postedNCT02058160

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Sanofin = 736Jan 2014 to Jul 2015

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.